Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis
2007

Modulation of Microglial Activation in Autoimmune Encephalomyelitis

Sample size: 41 publication Evidence: moderate

Author Information

Author(s): Bhasin Madhuri, Wu Muzhou, Tsirka Stella E

Primary Institution: University Medical Center at Stony Brook

Hypothesis

Can modulation of microglial/macrophage activation alter the disease course of experimental autoimmune encephalomyelitis (EAE)?

Conclusion

Modulating macrophage/microglial activity can significantly change the outcome of EAE, suggesting potential therapeutic strategies for multiple sclerosis.

Supporting Evidence

  • Intervention with MIF and tuftsin improved clinical scores in EAE.
  • Timing of microglial activation was critical for disease outcome.
  • MIF treatment at the onset of symptoms led to complete recovery.

Takeaway

This study shows that changing how brain immune cells work can help treat a disease that affects the nervous system.

Methodology

The study used pharmacological inhibitors and stimulators of microglial/macrophage activation in a mouse model of EAE to assess the effects on disease progression.

Limitations

The complexity of EAE and the timing of interventions may limit the generalizability of the findings.

Participant Demographics

Mice were used in the study, including wild-type and tPA-deficient strains.

Statistical Information

P-Value

0.0005

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2172-8-10

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication